SSA
BBIO icon

Schonfeld Strategic Advisors’s BridgeBio Pharma BBIO Stock Holding History

Schonfeld Strategic Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100,000
Closed -$1.67M – 2588
2021
Q4 		$1.67M Buy
+100,000
New +$4.23M 0.02% 750

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schonfeld Strategic Advisors's BBIO Position: Q3 2025 in Review

Schonfeld Strategic Advisors sold out of BridgeBio Pharma (BBIO) in Q3 2025, closing a stake of 14,530 shares — an estimated $627K sold.

Schonfeld Strategic Advisors first reported a position in BBIO in Q2 2020 and held it in 16 quarters. The position peaked at $5.08M in Q4 2023. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

  • Schonfeld Strategic Advisors reported no remaining BridgeBio Pharma position as of Q3 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 14,530 BridgeBio Pharma shares in Q3 2025, an estimated $627K.
  • Schonfeld Strategic Advisors first reported a position in BridgeBio Pharma in Q2 2020 and held it in 16 quarters.
  • Schonfeld Strategic Advisors's BridgeBio Pharma position peaked at $5.08M in Q4 2023.
  • 392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.